Good morning :)
Place Order
Add to Watchlist

Tatva Chintan Pharma Chem Ltd

TATVA

Tatva Chintan Pharma Chem Ltd

TATVA
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹2,118 cr, stock is ranked 1,121
Moderate RiskStock is 2.44x as volatile as Nifty
884.002.37% (-21.45)
884.002.37% (-21.45)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹2,118 cr, stock is ranked 1,121
Moderate RiskStock is 2.44x as volatile as Nifty

How to use scorecard? Learn more

MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹2,118 cr, stock is ranked 1,121
Moderate RiskStock is 2.44x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
120.142.870.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
30.643.481.33%

Forecast & Ratings

Detailed Forecast 
67%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Tatva Chintan Pharma Chem is engaged in the manufacturing business of chemical products.

Investor Presentation

View older 

Oct 25, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 14.08%, vs industry avg of 6.09%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.37% to 0.48%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 8.11%, vs industry avg of -1.55%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue137.29207.55264.62305.56442.54429.35401.01378.72
Raw Materialssubtract74.16118.57148.61156.06258.17220.39182.36326.62
Power & Fuel Costsubtract4.656.258.969.9222.6223.6134.78
Employee Costsubtract12.2716.3120.5323.8030.8141.2154.76
Selling & Administrative Expensessubtract16.1525.0427.1530.7051.9944.9439.13
Operating & Other expensessubtract5.456.022.7213.20-38.4636.2714.08
Depreciation/Amortizationsubtract2.954.024.796.738.189.5625.6126.29
Interest & Other Itemssubtract2.633.954.274.455.118.606.731.07
Taxes & Other Itemssubtract6.756.859.818.438.25-0.7013.227.11
EPS6.1110.2318.8126.0245.3820.5113.327.54
DPS0.000.000.005.002.002.002.002.00
Payout ratio0.000.000.000.190.040.100.150.27

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 25PDF
Jan 18PDF
FY 2023

Annual report

PDF

Investor Presentation

May 5PDF
Jan 24PDF
Nov 4PDF
Jul 25PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 25PDF
 

Peers & Comparison

Comparing 3 stocks from 
MaterialsSpecialty Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Tatva Chintan Pharma Chem Ltd69.812.870.22%
Gujarat Fluorochemicals Ltd105.217.710.07%
Vinati Organics Ltd61.398.060.37%
Akzo Nobel India Ltd43.6814.011.59%

Price Comparison

Compare TATVA with any stock or ETF
Compare TATVA with any stock or ETF
TATVA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 3.52%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.02%6.76%0.07%3.33%17.82%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

AugSepDec '23MarJunSep4.13%4.41%4.21%3.65%3.37%3.33%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 3.84%

Top 5 Mutual Funds holding Tatva Chintan Pharma Chem Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential MNC Fund - Growth - Direct Plan

Growth
0.6464%0.78%0.15%30/66 (-2)
ICICI Prudential Commodities Fund - Cumulative - Direct Plan

Growth
0.2271%0.20%-0.02%40/56 (-3)
ICICI Prudential Smallcap Fund - Growth - Direct Plan

Growth
0.0000%0.25%-0.03%0/119 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 6, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Sep 6, 2024

Cash Dividend

Ex DateEx DateSep 8, 2023

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Sep 8, 2023

Cash Dividend

Ex DateEx DateSep 8, 2022

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Sep 8, 2022

News & Opinions
Earnings
Tatva Chintan Pharma Chem reports consolidated net loss of Rs 0.66 crore in the September 2024 quarter

Net loss of Tatva Chintan Pharma Chem reported to Rs 0.66 crore in the quarter ended September 2024 as against net profit of Rs 7.78 crore during the previous quarter ended September 2023. Sales declined 13.63% to Rs 83.49 crore in the quarter ended September 2024 as against Rs 96.67 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.4996.67 -14 OPM %6.6820.94 - PBDT5.7917.99 -68 PBT-1.0211.21 PL NP-0.667.78 PL Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to discuss results

Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem AGM scheduled

Tatva Chintan Pharma Chem announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Purple Finance Ltd leads losers in ‘B’ group

3 months agoBusiness Standard

Tatva Chintan Pharma Chem consolidated net profit declines 45.16% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Tatva Chintan Pharma Chem consolidated net profit declines 45.16% in the June 2024 quarter

Net profit of Tatva Chintan Pharma Chem declined 45.16% to Rs 5.21 crore in the quarter ended June 2024 as against Rs 9.50 crore during the previous quarter ended June 2023. Sales declined 7.78% to Rs 105.46 crore in the quarter ended June 2024 as against Rs 114.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales105.46114.36 -8 OPM %11.9718.66 - PBDT13.4719.43 -31 PBT6.8113.42 -49 NP5.219.50 -45 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Tatva Chintan Pharma Chem to convene board meeting

Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Tatva Chintan Q4 Results Review - Revenue May Rise 25% With Expansion In Margin: ICICI Securities

6 months agoBloomberg Quint

Tatva Chintan - Delay In EU 7 Implementation Poses Risk To SDA Growth: Nirmal Bang

7 months agoBloomberg Quint

Accumulate Tatva Chintan Pharma Chem; target of Rs 1487: KR Choksey

9 months agoMoneycontrol